Slingshot members are tracking this event:

Gilead(GILD)'s Yescarta (Axicabtagene Ciloleucel) First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details
CAR T therapy is a breakthrough in hematologic cancer treatment in which a patient’s own T cells are engineered to seek and destroy cancer cells. CAR T therapy is manufactured specifically for each individual patient.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 18, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Yescarta, Axicabtagene Ciloleucel, Car-t Cells, B-cell Lymphoma, Dlbcl